map2 antibody Search Results


anti map2  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology anti map2
Anti Map2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti map2/product/Santa Cruz Biotechnology
Average 96 stars, based on 1 article reviews
anti map2 - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
chicken anti map2  (AvesLabs)
98
AvesLabs chicken anti map2
Chicken Anti Map2, supplied by AvesLabs, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chicken anti map2/product/AvesLabs
Average 98 stars, based on 1 article reviews
chicken anti map2 - by Bioz Stars, 2026-06
98/100 stars
  Buy from Supplier
phosphorylated erk  (Proteintech)
96
Proteintech phosphorylated erk
Phosphorylated Erk, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated erk/product/Proteintech
Average 96 stars, based on 1 article reviews
phosphorylated erk - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
nb300  (Novus Biologicals)
96
Novus Biologicals nb300
Nb300, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nb300/product/Novus Biologicals
Average 96 stars, based on 1 article reviews
nb300 - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
novusbiologicals nbp225156  (Novus Biologicals)
93
Novus Biologicals novusbiologicals nbp225156
Novusbiologicals Nbp225156, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/novusbiologicals nbp225156/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
novusbiologicals nbp225156 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
rabbit map2  (Novus Biologicals)
93
Novus Biologicals rabbit map2
A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of <t>MAP2</t> immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.
Rabbit Map2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit map2/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
rabbit map2 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
microtubule  (Boster Bio)
94
Boster Bio microtubule
A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of <t>MAP2</t> immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.
Microtubule, supplied by Boster Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/microtubule/product/Boster Bio
Average 94 stars, based on 1 article reviews
microtubule - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
map2 17490 1 ap  (Proteintech)
96
Proteintech map2 17490 1 ap
A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of <t>MAP2</t> immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.
Map2 17490 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/map2 17490 1 ap/product/Proteintech
Average 96 stars, based on 1 article reviews
map2 17490 1 ap - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
anti map2  (Biosensis ltd)
94
Biosensis ltd anti map2
A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of <t>MAP2</t> immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.
Anti Map2, supplied by Biosensis ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti map2/product/Biosensis ltd
Average 94 stars, based on 1 article reviews
anti map2 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
mouse anti map2  (Novus Biologicals)
93
Novus Biologicals mouse anti map2
A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of <t>MAP2</t> immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.
Mouse Anti Map2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti map2/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
mouse anti map2 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
anti map2 goat polyclonal igg antibody  (PhosphoSolutions)
96
PhosphoSolutions anti map2 goat polyclonal igg antibody
Fig. 3 | Role of the UPR and Wnt/β-catenin signaling in nuclear REST induction. a Immunolabeling of UPR activation (marker BiP/GRP78, red), REST (green), β- catenin (magenta) and DNA (DAPI, blue) in 11-month-old 3xTg and WT mice shows coordinate upregulation of BiP, nuclear REST and nuclear β-catenin expression in 3xTg mice. b Correlation between nuclear β-catenin and nuclear REST (left graph), BiP and nuclear REST (middle graph) and BiP and nuclear β-catenin (right graph) levels in the hippocampus CA1 region of 11-month-old 3xTg mice. Shown are the mean fluorescence intensity values for nuclear REST in individual CA1 neurons from n = 3 3xTg mice. a.u.- arbitrary units. The Pearson correlation coefficient (r) and P- value are shown. c Immunolabeling of REST (green) and neuron marker <t>MAP2</t> (red) in 3xTg primary cortical neurons (PCNs) shows nuclear REST in neurons treated with vehicle and decreased nuclear REST in 3xTg neurons after a 24-h treatment with the Wnt/β-catenin inhibitors Dickkopf 1 (DKK1), XAV939 and ICG001, or the PERK inhibitor GSK2606414. d Quantification of average nuclear REST levels in WT PCNs, as well as 3xTg PCNs treated with vehicle or the individual drugs. The P-
Anti Map2 Goat Polyclonal Igg Antibody, supplied by PhosphoSolutions, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti map2 goat polyclonal igg antibody/product/PhosphoSolutions
Average 96 stars, based on 1 article reviews
anti map2 goat polyclonal igg antibody - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

Image Search Results


A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of MAP2 immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.

Journal: bioRxiv

Article Title: Tau oligomers modulate synapse fate by eliciting progressive bipartite synapse dysregulation and synapse loss

doi: 10.1101/2025.09.19.677215

Figure Lengend Snippet: A Workflow indicating that the 30-min treatment with tau oligomers was followed by different intervals of time (30 min, 1 hour, 24 hours, 7, or 14 days) before the fixation of human neuron cultures for experiments. B Confocal images of human neurons treated with oligomerized tau conjugated with Fluorescein-5-isothiocyanate (tau-FITC) (green) showed colocalization (white arrowheads) of tau-FITC with Synapsin (blue) and PSD-95 (red). Scale bar: 5 μm. C Representative confocal images of human neurons at 30 min, 1 hour and 24 hours after the 30 min exposure with oligomerized tau-FITC as described in A . Scale bar: 5 μm. D Quantification of the integrated intensity of tau-FITC fluorescence at synapses in human neurons that were treated with oligomerized tau-FITC for 30 min and fixed at different time points A (n = 12 images/group; ** p < 0.01, *** p < 0.001, one-way ANOVA, Bonferroni post hoc analyses). E, F Representative images of NeuN immunolabeling, as a neuronal marker, in vehicle-treated control neurons and in neurons at either ( E ) 7 or ( F ) 14 days after the 30-min exposure to tau oligomers. The density of NeuN-positive cells in the cultures was calculated and compared with or without tau oligomer exposure (n = 12 images/group; no significant difference, Unpaired Student’s t -test). Scale bar: 100 mm. G, H Representative confocal images of MAP2 immunostaining in neurons at ( G ) 7 or ( H ) 14 days after the 30-min tau oligomer treatment and in neurons treated with vehicle control. Scale bars: 20 μm. The intensity of MAP2 immunolabeling in dendrites of human neurons was quantified at ( G ) 7 days (n = 12 images/group; no significant difference, Unpaired Student’s t -test) and ( H ) 14 days (n = 12 images/group; *** p < 0.001, Unpaired Student’s t -test) post-oligomer exposure. Values are given as means ± SEM.

Article Snippet: Primary antibodies used for western blot and immunocytochemistry were: Tau5 (AB_80579, Abcam), Streptavin HRP (S911, Invitrogen), GAPDH (MAB374, Sigma), Rabbit FLAG (F7425, Sigma), Mouse FLAG (F3165, Sigma), PSD-95 (MA1046, ThermoFisher), GluA2/3 (AB1506, MilliporeSigma), Cy3 Streptavidin (AB_2337244, Jackson Immunoresearch), Mouse vGluT1 (MAB5502, MilliporeSigma), Guinea Pig vGluT1 (AB5905, MilliporeSigma), GluA1 (ABN241, MilliporeSigma), GluN1 (114 011, SynapticSystems), Synapsin (5297S, Cell Signaling), Rabbit MAP2 (4542S, Cell Signaling), Chicken MAP2 (NB300 213, Novus Biologicals), NeuN (AB177487, Abcam), GFAP (PA110004, Invitrogen) Secondary antibodies used were: Anti-mouse Alexa Fluor 488 (115-545-166, Jackson Immunoresearch), Anti-guinea pig Alexa Fluor 546 (A-11074, Life Technologies), Anti-mouse Alexa Fluor 546 (A-11030, Invitrogen), Anti-rabbit Alexa Fluor 647 (111-605-144, Jackson Immunoresearch), Anti-chicken Alexa Fluor 647 (A32933, Invitrogen)

Techniques: Fluorescence, Immunolabeling, Marker, Control, Immunostaining

Fig. 3 | Role of the UPR and Wnt/β-catenin signaling in nuclear REST induction. a Immunolabeling of UPR activation (marker BiP/GRP78, red), REST (green), β- catenin (magenta) and DNA (DAPI, blue) in 11-month-old 3xTg and WT mice shows coordinate upregulation of BiP, nuclear REST and nuclear β-catenin expression in 3xTg mice. b Correlation between nuclear β-catenin and nuclear REST (left graph), BiP and nuclear REST (middle graph) and BiP and nuclear β-catenin (right graph) levels in the hippocampus CA1 region of 11-month-old 3xTg mice. Shown are the mean fluorescence intensity values for nuclear REST in individual CA1 neurons from n = 3 3xTg mice. a.u.- arbitrary units. The Pearson correlation coefficient (r) and P- value are shown. c Immunolabeling of REST (green) and neuron marker MAP2 (red) in 3xTg primary cortical neurons (PCNs) shows nuclear REST in neurons treated with vehicle and decreased nuclear REST in 3xTg neurons after a 24-h treatment with the Wnt/β-catenin inhibitors Dickkopf 1 (DKK1), XAV939 and ICG001, or the PERK inhibitor GSK2606414. d Quantification of average nuclear REST levels in WT PCNs, as well as 3xTg PCNs treated with vehicle or the individual drugs. The P-

Journal: Nature communications

Article Title: A neurodegeneration checkpoint mediated by REST protects against the onset of Alzheimer's disease.

doi: 10.1038/s41467-023-42704-6

Figure Lengend Snippet: Fig. 3 | Role of the UPR and Wnt/β-catenin signaling in nuclear REST induction. a Immunolabeling of UPR activation (marker BiP/GRP78, red), REST (green), β- catenin (magenta) and DNA (DAPI, blue) in 11-month-old 3xTg and WT mice shows coordinate upregulation of BiP, nuclear REST and nuclear β-catenin expression in 3xTg mice. b Correlation between nuclear β-catenin and nuclear REST (left graph), BiP and nuclear REST (middle graph) and BiP and nuclear β-catenin (right graph) levels in the hippocampus CA1 region of 11-month-old 3xTg mice. Shown are the mean fluorescence intensity values for nuclear REST in individual CA1 neurons from n = 3 3xTg mice. a.u.- arbitrary units. The Pearson correlation coefficient (r) and P- value are shown. c Immunolabeling of REST (green) and neuron marker MAP2 (red) in 3xTg primary cortical neurons (PCNs) shows nuclear REST in neurons treated with vehicle and decreased nuclear REST in 3xTg neurons after a 24-h treatment with the Wnt/β-catenin inhibitors Dickkopf 1 (DKK1), XAV939 and ICG001, or the PERK inhibitor GSK2606414. d Quantification of average nuclear REST levels in WT PCNs, as well as 3xTg PCNs treated with vehicle or the individual drugs. The P-

Article Snippet: Additional primary antibodies were as follows: anti-human Aβ rabbit monoclonal IgG antibody (Cell Signaling, Cat. No. 8243); antihuman APP mouse monoclonal IgG antibody (clone 6E10; Covance, Catalog No. SIG-39320); anti-actin mouse monoclonal IgG antibody (clone ACTN05 (C4); ThermoFisher Scientific, CatalogNo.MA5-11869); anti-NeuN mouse monoclonal IgG antibody (clone A60, Millipore, MAB377); anti-MAP2 goat polyclonal IgG antibody (PhosphoSolutions, Catalog. No. 1099-MAP2); anti-CDK5 mouse monoclonal IgG antibody (clone 4E4; Novus Bio, Catalog No. NBP2-37602); anti-GSK3β mouse monoclonal IgG antibody (clone D5C5Z; Novus Bio, catalog No. NBP147470S); anti-PS1 C-terminal (CTF) rabbit monoclonal IgG antibody (clone EP2000Y; Abcam, Catalog No. ab76083); anti-PS1 N-terminal (NTF) rabbit polyclonal IgG antibody (231-f; made in the Yankner lab); anti-Nicastrin mouse monoclonal IgG antibody (clone 9C3; Biolegend, Catalog No. 852301); anti-Nicastrin rabbit polyclonal IgG antibody (Sigma Millipore, Catalog No. N1660); anti-PEN2 rabbit polyclonal IgG antibody (ProScience, Catalog No.3981); anti-PEN2 rabbit monoclonal IgG antibody (clone EPR9200; Abcam, Catalog No. ab154830); antiPEN2 rabbit polyclonal IgG (ProScience, Catalog No. 3981); antiTransferrin receptor mouse monoclonal IgG antibody (clone H68.4; ThermoFisher Scientific, Catalog No. 13-6800); anti-BiP/GRP78 mouse monoclonal IgG (clone C38; ThermoFisher Scientific, clone C38, CatalogNo.

Techniques: Immunolabeling, Activation Assay, Marker, Expressing

Fig. 5 | REST suppresses the tau kinases CDK5 and GSK3β. a, b Loss of REST in excitatory neurons increases CDK5 expression in cortex and hippocampus. aImmunolabelingforCDK5(green)andthe neuronalmarkerMAP2(magenta)in CA1 neurons of the hippocampus in 9-month-old 3xTg and 3xTg;cKO mice. b Quantification of CDK5 immunofluorescence intensity in the hippocampus and cortex of 9-month-old 3xTg (n = 4) and 3xTg;cKO (n = 4) mice. c, d Loss of a single REST allele increases CDK5 expression. c Immunolabeling for CDK5 (green) and MAP2 (magenta) in 29-month-old 3xTg and 3xTg;GT (heterozygous REST null) mice. d Quantification of CDK5 immunofluorescence intensity in 28–29-month-old 3xTg (n = 6) and 3xTg;GT (n = 6) mice. e, f Loss of REST in excitatory neurons increases GSKβ expression in cortex and hippocampus. e Immunolabeling for GSK3β (green) and MAP2 (magenta) in hippocampal CA1 neurons in 9-month-old 3xTg and 3xTg;cKO mice. f Quantification of GSK3β immunofluorescenceintensityin9-month-old3xTg(n = 4)and3xTg;cKO (n = 4) mice. g, h Loss of a single REST allele increases GSK3β expression.

Journal: Nature communications

Article Title: A neurodegeneration checkpoint mediated by REST protects against the onset of Alzheimer's disease.

doi: 10.1038/s41467-023-42704-6

Figure Lengend Snippet: Fig. 5 | REST suppresses the tau kinases CDK5 and GSK3β. a, b Loss of REST in excitatory neurons increases CDK5 expression in cortex and hippocampus. aImmunolabelingforCDK5(green)andthe neuronalmarkerMAP2(magenta)in CA1 neurons of the hippocampus in 9-month-old 3xTg and 3xTg;cKO mice. b Quantification of CDK5 immunofluorescence intensity in the hippocampus and cortex of 9-month-old 3xTg (n = 4) and 3xTg;cKO (n = 4) mice. c, d Loss of a single REST allele increases CDK5 expression. c Immunolabeling for CDK5 (green) and MAP2 (magenta) in 29-month-old 3xTg and 3xTg;GT (heterozygous REST null) mice. d Quantification of CDK5 immunofluorescence intensity in 28–29-month-old 3xTg (n = 6) and 3xTg;GT (n = 6) mice. e, f Loss of REST in excitatory neurons increases GSKβ expression in cortex and hippocampus. e Immunolabeling for GSK3β (green) and MAP2 (magenta) in hippocampal CA1 neurons in 9-month-old 3xTg and 3xTg;cKO mice. f Quantification of GSK3β immunofluorescenceintensityin9-month-old3xTg(n = 4)and3xTg;cKO (n = 4) mice. g, h Loss of a single REST allele increases GSK3β expression.

Article Snippet: Additional primary antibodies were as follows: anti-human Aβ rabbit monoclonal IgG antibody (Cell Signaling, Cat. No. 8243); antihuman APP mouse monoclonal IgG antibody (clone 6E10; Covance, Catalog No. SIG-39320); anti-actin mouse monoclonal IgG antibody (clone ACTN05 (C4); ThermoFisher Scientific, CatalogNo.MA5-11869); anti-NeuN mouse monoclonal IgG antibody (clone A60, Millipore, MAB377); anti-MAP2 goat polyclonal IgG antibody (PhosphoSolutions, Catalog. No. 1099-MAP2); anti-CDK5 mouse monoclonal IgG antibody (clone 4E4; Novus Bio, Catalog No. NBP2-37602); anti-GSK3β mouse monoclonal IgG antibody (clone D5C5Z; Novus Bio, catalog No. NBP147470S); anti-PS1 C-terminal (CTF) rabbit monoclonal IgG antibody (clone EP2000Y; Abcam, Catalog No. ab76083); anti-PS1 N-terminal (NTF) rabbit polyclonal IgG antibody (231-f; made in the Yankner lab); anti-Nicastrin mouse monoclonal IgG antibody (clone 9C3; Biolegend, Catalog No. 852301); anti-Nicastrin rabbit polyclonal IgG antibody (Sigma Millipore, Catalog No. N1660); anti-PEN2 rabbit polyclonal IgG antibody (ProScience, Catalog No.3981); anti-PEN2 rabbit monoclonal IgG antibody (clone EPR9200; Abcam, Catalog No. ab154830); antiPEN2 rabbit polyclonal IgG (ProScience, Catalog No. 3981); antiTransferrin receptor mouse monoclonal IgG antibody (clone H68.4; ThermoFisher Scientific, Catalog No. 13-6800); anti-BiP/GRP78 mouse monoclonal IgG (clone C38; ThermoFisher Scientific, clone C38, CatalogNo.

Techniques: Expressing, Immunolabeling